四种海马及内耳保护并同步整合加量的全脑放疗方案用于有限脑转移瘤的剂量学评估
本研究利用10例有限(1-5个)脑转移瘤患者的CT/MRI数据,重新规划sIMRT、dIMRT、VMAT和螺旋断层放疗四种同步整合加量全脑放疗方案,处方剂量为转移灶40-50 Gy/10次、全脑30 Gy/10次,海马剂量满足RTOG 0933标准(Dmax≤17 Gy,D100%≤10 Gy),内耳Dmean≤15 Gy。所有方案均满足剂量限制,PTVmets覆盖率为97.1%-99.4%,螺旋断层放疗获得最佳的PTVbrain覆盖和均匀性。
要点
- 四种同步整合加量全脑放疗方案均满足海马及内耳剂量限制。
- 转移灶PTV覆盖率为97.1%-99.4%。
- 螺旋断层放疗的PTVbrain覆盖和均匀性最佳。
核心结论
- 四种放疗方案均产生可接受的治疗计划,海马和内耳保护良好。
- 螺旋断层放疗获得满意的PTVbrain覆盖和最佳的均匀性指数。
研究设计与样本
- 利用10例有限(1-5个)脑转移瘤患者的CT/MRI数据进行剂量学比较研究。
- 重新规划step-and-shoot调强放疗(sIMRT)、动态调强放疗(dIMRT)、容积旋转调强放疗(VMAT)和螺旋断层放疗(Tomo)四种同步整合加量全脑放疗方案。
- 处方剂量为转移灶40-50 Gy/10次、全脑30 Gy/10次同步照射。
- 海马剂量满足RTOG 0933海马保护标准(Dmax≤17 Gy,D100%≤10 Gy),内耳剂量限制为Dmean≤15 Gy。
主要发现
- 所有计划均满足规定的剂量限制。
- 转移灶计划靶区(PTVmets)平均覆盖率范围为97.1%至99.4%。
- 对全脑计划靶区(PTVbrain),Tomo提供最低的平均D2%(37.5±2.8 Gy)、最高的平均D98%(25.2±2.0 Gy)以及最佳的靶区覆盖(92.6%±2.1%)和适形性指数(0.79±0.06)。
- 两种固定机架调强放疗方式(sIMRT和dIMRT)提供相似的PTVbrain剂量均匀性(均为0.76)。
- 四种方案间在海马最大和最小剂量以及眼、晶状体和视神经最大剂量方面观察到显著差异。
关键数值与推荐
- 海马剂量限制:Dmax≤17 Gy,D100%≤10 Gy(RTOG 0933标准)。
- 内耳剂量限制:Dmean≤15 Gy。
- 处方剂量:转移灶40-50 Gy/10次,全脑30 Gy/10次。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: To perform a dosimetric evaluation of four different simultaneous integrated boost whole brain radiotherapy modalities with hippocampus and inner ear avoidance in the treatment of limited brain metastases. METHODS: Computed tomography/magnetic resonance imaging data of 10 patients with limited (1-5) brain metastases were used to replan step-and-shoot intensity-modulated radiotherapy (sIMRT), dynamic intensity-modulated radiation therapy (dIMRT), volumetric-modulated arc therapy (VMAT), and helical tomotherapy (Tomo). The prescribed doses of 40-50 Gy in 10 fractions and 30 Gy in 10 fractions were simultaneously delivered to the metastatic lesions and the whole-brain volume, respectively. The hippocampal dose met the RTOG 0933 criteria for hippocampal avoidance (Dmax ≤17 Gy, D100% ≤10 Gy). The inner ear dose was restrained to Dmean ≤15 Gy. Target coverage (TC), homogeneity index (HI), conformity index (CI), maximum dose (Dmax), minimum dose (Dmin) and dose to organs at risk (OARs) were compared. RESULTS: All plans met the indicated dose restrictions. The mean percentage of planning target volume of metastases (PTVmets) coverage ranged from 97.1 to 99.4%. For planning target volume of brain (PTVbrain), Tomo provided the lowest average D2% (37.5 ± 2.8 Gy), the highest average D98% (25.2 ± 2.0 Gy), and the best TC (92.6% ± 2.1%) and CI (0.79 ± 0.06). The two fixed gantry IMRT modalities (step and shot, dynamic) provided similar PTVbrain dose homogeneity (both 0.76). Significant differences across the four approaches were observed for the maximum and minimum doses to the hippocampus and the maximum doses to the eyes, lens and optic nerves. CONCLUSION: All four radiotherapy modalities produced acceptable treatment plans with good avoidance of the hippocampus and inner ear. Tomo obtained satisfactory PTVbrain coverage and the best homogeneity index. TRIAL REGISTRATION: Clinicaltrials.gov, NCT03414944 . Registered 29 January 2018.
引用
- Jiang A, Sun W, Zhao F, et al. Dosimetric evaluation of four whole brain radiation therapy approaches with hippocampus and inner ear avoidance and simultaneous integrated boost for limited brain metastases. Radiat Oncol. 2019. PMID: 30876444. doi:10.1186/s13014-019-1255-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。